| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Mar'17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Collaboration revenue | ||||||||||||
1,984 | 1,666 | 2,299 | 3,460 | 4,463 | 5,322 | 0 | 0 | 0 | - | - | - | - |
Operating expenses: | ||||||||||||
Research and development | ||||||||||||
98,172 | 89,398 | 85,321 | 73,024 | 60,487 | 47,948 | 41,256 | 32,809 | 26,575 | 21,378 | 0 | 0 | 0 |
General and administrative | ||||||||||||
25,124 | 22,211 | 21,535 | 19,340 | 18,329 | 17,300 | 14,884 | 12,759 | 10,214 | 8,279 | 0 | 0 | 0 |
Total operating expenses | ||||||||||||
123,296 | 111,609 | 106,856 | 92,364 | 78,816 | 65,248 | 56,141 | 45,568 | 36,790 | 29,657 | 0 | 0 | 0 |
Loss from operations | ||||||||||||
-121,312 | -109,943 | -104,557 | -88,904 | -74,353 | -59,926 | -52,015 | -43,044 | -35,661 | -29,657 | 0 | 0 | 0 |
Other income: | ||||||||||||
Changes in fair value of convertible preferred stock tranche liability | ||||||||||||
- | - | - | - | - | - | - | - | - | 876 | 0 | 0 | 0 |
Interest income | ||||||||||||
5,917 | 6,027 | 6,022 | 5,848 | 5,141 | 4,349 | 3,318 | 1,968 | 1,008 | 542 | 0 | 0 | 0 |
Total other income | ||||||||||||
5,917 | 6,027 | 6,022 | 5,848 | 5,141 | 4,349 | 3,318 | 1,968 | 1,008 | -334 | 0 | 0 | 0 |
Net loss | ||||||||||||
-115,395 | -103,916 | -98,535 | -83,056 | -69,212 | -55,577 | -48,696 | -41,076 | -34,653 | -29,991 | 0 | 0 | 0 |
Net loss per share-basic and diluted | ||||||||||||
-0.78 | -0.55 | -0.67 | -0.61 | -0.64 | 2.86 | -0.38 | -0.34 | -4.09 | -3.92 | -2.78 | -2.61 | -2.79 |
Weighted-average common shares outstanding-basic and diluted | ||||||||||||
45,151 | 44,105 | 43,904 | 43,075 | 37,384 | 37,573 | 37,273 | 36,860 | 2,500 | 3,278 | 2,351 | 2,296 | 1,992 |